Optimization of the treatment of anxiety disorders with selank
V. E. Medvedev, O. N. Tereshchenko, N. V. Kost, A. Y. Ter-Israelyan, E. V. Gushanskaya, I. K. Chobanu, O. Y. Sokolov, N. F. Myasoedov · 2015 · Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33–40
What does this source report?
The authors report earlier symptom improvement and fewer unwanted effects with adjunctive Selank. Both groups received phenazepam.
- Population and setting
- 70 patients: 40 Selank plus phenazepam; 30 phenazepam alone
- Evidence type
- Human comparative study
- Preparation
- See the original report; formulation details require verification.
- Source language
- See linked publication
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Does not isolate Selank monotherapy.
- Allocation and blinding unresolved; a combination comparison is not general evidence of safety.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Journal article
Review depth: Abstract
Source access and review scope
Indexed abstract checked; allocation, blinding and full outcome tables not reviewed.
Recorded source-check date: 2026-10-02. This date does not imply a completed systematic review.
Cite and trace this record
Original source: V. E. Medvedev, O. N. Tereshchenko, N. V. Kost, A. Y. Ter-Israelyan, E. V. Gushanskaya, I. K. Chobanu, O. Y. Sokolov, N. F. Myasoedov. Optimization of the treatment of anxiety disorders with selank Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33–40 2015.
Molekul research summary: https://molekul.io/research/selank-26356395. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry